<DOC>
	<DOCNO>NCT01224834</DOCNO>
	<brief_summary>The purpose study determine safety tolerability several dos ragweed pollen allergen extract administer sublingual tablet subject allergic rhinitis ragweed .</brief_summary>
	<brief_title>Safety Tolerability Study Ragweed SLIT Tablets</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<criteria>write consent male female subject 18 yo 60 year old general good health woman child bear potential : negative urine pregnancy test use medically effective contraceptive method symptom ragweed pollen induce allergic rhinitis least last 2 year sensitization ragweed pollen demonstrate positive skin prick test ragweed pollen specific IgE level ( ragweed pollen ) &gt; 0.70 kU/l screen FEV1 least 80 % predict value screen past current disease , judge investigator , may affect outcome study history lifethreatening asthma asthma require daily treatment ( whatever pharmaceutical class ) pregnant lactate woman subject previously receive desensitisation treatment ragweed pollen and/or Asteraceae plan start desensitisation treatment study symptom treatment phase due sensitivity second allergen subject treat ongoing immunotherapy another allergen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Ragweed , allergy , sublingual immunotherapy</keyword>
</DOC>